转移性去势抵抗性前列腺癌患者SARS-CoV-2感染的发生率与结局
既往针对mCRPC的治疗数量与死亡率显著相关(p=0.004),提示ADT在转移性前列腺癌中的保护作用可能较弱。
要点
- mCRPC患者SARS-CoV-2感染发生率为2.3%,住院率64.7%,死亡率38.2%。
- 既往mCRPC治疗数量与死亡风险显著相关(p=0.004)。
- ADT对转移性前列腺癌患者的保护作用可能有限。
核心结论
- mCRPC患者感染SARS-CoV-2后死亡率为38.2%,既往mCRPC治疗数量显著影响死亡率(p=0.004)。
- ADT在转移性前列腺癌患者中的 postulated 保护作用可能较弱。
研究设计与样本
- 主要研究终点为死亡率及前列腺癌相关病史和治疗对死亡率的影响。
主要发现
- 中位随访21天(四分位距13-41天)后,13例(38.2%)死亡,17例(50.0%)康复,4例(11.7%)仍感染。
- 既往mCRPC治疗数量对死亡率有显著影响(p=0.004)。
临床怎么用
- 临床应关注mCRPC患者SARS-CoV-2感染的严重结局,尤其是既往多线治疗者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with cancer are at increased risk of complicated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but it is still unclear if the risk of mortality is influenced by cancer type or ongoing anti-cancer treatments. An interesting debate concerning the potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in the case of prostate cancer (PC), and the aim of this multi-centre cohort study was to investigate the incidence and outcomes of SARS-CoV-2 infection in patients with metastatic castration-resistant prostrate cancer (mCRPC). PATIENTS AND METHODS: We retrospectively reviewed the clinical records of patients with mCRPC who developed SARS-CoV-2 infection, and recorded their baseline clinical characteristics, their history of PC and SARS-CoV-2 infection, and their oncological status and treatment at the time of infection. The primary study end point was the death rate and the possible impact of the patients' PC-related history and treatments on mortality. RESULTS: Thirty-four of the 1433 patients with mCRPC attending the participating centres (2.3%) developed SARS-CoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnoea (61.8%), cough (52.9%) and fatigue (38.2%). After a median follow-up of 21 days (interquartile range: 13-41), 13 patients had died (38.2%), 17 recovered (50.0%) and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mortality (p = 0.004). CONCLUSIONS: Our findings contribute additional data to the current debate concerning the postulated protective role of ADT, which seems to be less in patients with metastatic PC.
引用
- Caffo O, Gasparro D, Di Lorenzo G, et al. Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020. PMID: 33091718. doi:10.1016/j.ejca.2020.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。